Physician profile
Christopher J Davis
NPI 1184726820
$1,246.36
in general payments reported to CMS, 2019-2025
25 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.79 · 2021: $115 · 2022: $176 · 2023: $412 · 2024: $87.90 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $410.75 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Daiichi Sankyo INC. | $106.12 | 2025 | Injectafer |
| Pfizer INC. | $70.63 | 2022-2024 | |
| Novo Nordisk INC | $68.94 | 2021-2025 | Ozempic |
| Sumitomo Pharma America, INC. | $57.94 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.50 | 2025 | Xifaxan |
| Esperion Therapeutics, INC. | $46.94 | 2025 | Nexletol |
| Lilly USA, LLC | $41.32 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $38.72 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.68 | 2025 | |
| Inspire Medical Systems, INC. | $31.70 | 2023 | Inspire |
| Glaxosmithkline, LLC. | $31.26 | 2019-2023 | Arexvy, Shingrix |
| Astellas Pharma US INC | $30.17 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $27.41 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $25.90 | 2022-2023 | Farxiga |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $23.58 | 2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $23.29 | 2022 | |
| Dexcom, INC. | $17.99 | 2023 | Dexcom G6 Transmitter |
| Lundbeck LLC | $17.54 | 2025 | Rexulti |
| Exact Sciences Corporation | $16.77 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $16.29 | 2022 | |
| Abbott Laboratories | $14.33 | 2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $13.20 | 2021 | |
| Phathom Pharmaceuticals, INC. | $12.33 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.